LIFR and neoplasm: Both pharmacologic blockade of the LIF receptor and genetic Lifr deletion in pancreatic epithelial cells significantly slowed down tumor progression and improved chemotherapy efficacy to increase survival in PDAC mouse models, highlighting a critical role for stroma-derived LIF in PDAC progression as well as chemoresistance (Figure 2C).